Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...
That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...
Amgen's MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up to 25% Amgen Inc.'s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback